tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

4D Molecular Therapeutics Inc

FDMT
Add to Watchlist
14.710USD
-0.290-1.93%
Close 09-23 16:00（ET）
769.04MMarket Cap
LossP/E TTM
After-hours 16:30 (ET)14.430USD-0.295-2.00%

4D Molecular Therapeutics Inc

14.710
-0.290-1.93%
Overview
News&Analysis
Financials
Stock Score
Technical
Forecast
Ownership
Dividends
Profile
Discussions
Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

FDMT Financials

See 4D Molecular Therapeutics Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Key Financial Ratios

Market Cap
769.04M
Dividend TTM
0.00
P/E TTM
-5.73
EPS TTM
-2.57
Revenue
85.21M
Net Profit
-160.87M
ROE
-34.92%
ROA
-31.28%

4D Molecular Therapeutics Inc Earnings Date

Latest Release
Aug 13, 2026
EPS / Forecast
-1.04/-1.02
Revenue / Forecast
3.78M/3.10M

Financial Statement Highlights

Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
-6.20%-1.04
-17.39%-1.01
133.99%0.30
-28.41%-1.01
-54.57%-0.98
-30.87%-0.86
---0.89
-225.16%-0.79
18.16%-0.63
24.97%-0.66
----
---0.24
---0.77
---0.88
---0.84
---2.48
----
----
----
----
----
Revenue
25106.67%3.78M
21664.29%3.05M
8508900.00%85.09M
2900.00%90.00K
200.00%15.00K
-50.00%14.00K
--1.00K
-99.99%3.00K
-97.91%5.00K
-90.60%28.00K
----
3940.80%20.20M
47.53%239.00K
-75.55%298.00K
1255.43%1.25M
-63.40%500.00K
-98.89%162.00K
-39.05%1.22M
--92.00K
--1.37M
--14.58M
Net Profit
-33.44%-72.94M
-43.33%-68.76M
139.05%19.40M
-29.73%-56.88M
-56.38%-54.66M
-48.06%-47.97M
---49.67M
-327.49%-43.84M
-18.02%-34.95M
-12.97%-32.40M
----
60.08%-10.26M
-5.45%-29.62M
-8.90%-28.68M
-9.15%-27.38M
-15.52%-25.69M
-270.09%-28.09M
-60.54%-26.34M
---25.08M
---22.24M
---7.59M
Net Margin
99.47%-1929.01%
99.34%-2256.65%
100.00%22.80%
95.68%-63195.56%
47.87%-364386.67%
-196.11%-342657.14%
---4967100.00%
-2878877.80%-1461433.33%
-5541.39%-699060.00%
-1102.28%-115717.86%
----
---50.76%
---12391.63%
---9624.83%
---2195.59%
---4256.91%
----
----
----
----
----
Gross Margin
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
--100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
----
--100.00%
--100.00%
--100.00%
--100.00%
--100.00%
----
----
----
----
----
Debt to assets ratio
--3.98%
----
----
----
----
----
----
----
----
--0.00%
--0.00%
----
----
----
--0.00%
--0.00%
----
----
----
----
----
Income Statement
Revenue
25106.67%3.78M
21664.29%3.05M
8508900.00%85.09M
2900.00%90.00K
200.00%15.00K
-50.00%14.00K
--1.00K
-99.99%3.00K
-97.91%5.00K
-90.60%28.00K
----
3940.80%20.20M
47.53%239.00K
-75.55%298.00K
1255.43%1.25M
-63.40%500.00K
-98.89%162.00K
-39.05%1.22M
--92.00K
--1.37M
--14.58M
Operating profit
-29.55%-77.03M
-37.30%-73.62M
126.22%14.71M
-19.66%-61.19M
-40.04%-59.46M
-40.60%-53.62M
---56.12M
-265.91%-51.13M
-32.11%-42.46M
-26.67%-38.14M
----
47.26%-13.97M
-13.05%-32.14M
-14.07%-30.11M
-15.97%-28.72M
-16.92%-26.50M
-274.22%-28.43M
-61.79%-26.39M
---24.76M
---22.66M
---7.60M
Net Profit
-33.44%-72.94M
-43.33%-68.76M
139.05%19.40M
-29.73%-56.88M
-56.38%-54.66M
-48.06%-47.97M
---49.67M
-327.49%-43.84M
-18.02%-34.95M
-12.97%-32.40M
----
60.08%-10.26M
-5.45%-29.62M
-8.90%-28.68M
-9.15%-27.38M
-15.52%-25.69M
-270.09%-28.09M
-60.54%-26.34M
---25.08M
---22.24M
---7.59M
Balance Sheet
Current assets
26.27%382.96M
21.89%405.36M
-5.01%413.13M
-38.84%312.38M
-45.12%303.29M
-37.91%332.57M
46.65%434.93M
55.60%510.76M
73.91%552.63M
158.69%535.59M
34.50%296.59M
41.19%328.24M
28.90%317.78M
-14.81%207.04M
-13.96%220.51M
40.27%232.48M
-0.90%246.52M
-8.11%243.05M
-9.33%256.28M
79.10%165.73M
----
Total current liabilities
37.48%47.67M
61.36%43.40M
50.90%43.98M
25.94%37.11M
78.72%34.68M
63.99%26.90M
53.81%29.15M
62.23%29.46M
41.12%19.40M
45.44%16.40M
20.47%18.95M
33.91%18.16M
-4.06%13.75M
-6.72%11.28M
-3.72%15.73M
19.26%13.56M
45.20%14.33M
-13.11%12.09M
-2.42%16.34M
-20.35%11.37M
----
Total assets
4.01%492.62M
-0.55%512.90M
1.13%566.71M
-29.81%423.98M
-23.62%473.64M
-18.12%515.73M
64.87%560.38M
67.04%604.03M
75.92%620.12M
158.13%629.88M
29.81%339.89M
29.07%361.61M
16.36%352.50M
-24.90%244.02M
-25.92%261.85M
16.44%280.16M
18.83%302.94M
20.29%324.93M
22.60%353.49M
145.05%240.62M
----
Total liabilities
61.06%84.96M
32.74%61.07M
22.64%61.05M
7.67%55.00M
65.99%52.75M
56.89%46.01M
55.26%49.78M
61.24%51.08M
16.15%31.78M
15.38%29.32M
5.09%32.06M
10.30%31.68M
-10.06%27.36M
-11.97%25.41M
-11.26%30.51M
74.23%28.72M
112.90%30.42M
4.29%28.87M
7.63%34.38M
-41.20%16.48M
----
Total equity
-3.14%407.66M
-3.81%451.84M
-0.97%505.66M
-33.27%368.98M
-28.46%420.89M
-21.79%469.72M
65.87%510.61M
67.59%552.95M
80.95%588.34M
174.72%600.56M
33.07%307.83M
31.22%329.93M
19.31%325.14M
-26.16%218.61M
-27.50%231.34M
12.18%251.44M
13.24%272.52M
22.12%296.06M
24.46%319.11M
219.48%224.13M
----
Cash Flow Statement
Net operating income
-61.37%-70.00M
-42.65%-68.13M
162.25%28.55M
-58.20%-46.50M
-43.43%-43.38M
-64.18%-47.76M
-86.06%-45.86M
-2409.91%-29.39M
-37.06%-30.24M
-4.24%-29.09M
-10.97%-24.65M
94.43%-1.17M
-10.86%-22.07M
-18.50%-27.91M
-1.73%-22.21M
-33.69%-21.02M
-22.83%-19.90M
-53.20%-23.55M
-24.78%-21.84M
---15.72M
----
Net investment
284.41%25.54M
115.63%68.89M
-1925.29%-128.85M
-34.88%17.78M
81.16%-13.85M
112.14%31.95M
205.64%7.06M
-8.94%27.30M
-249.20%-73.54M
-710.38%-263.26M
81.32%-6.68M
95.05%29.98M
-14.23%49.29M
179.71%43.13M
-10.80%-35.78M
111.06%15.37M
7897.56%57.47M
-8328.35%-54.11M
-6256.50%-32.29M
---139.01M
----
Net financing
4811.72%42.34M
--11.48M
18532.61%111.98M
-79.58%116.00K
-95.00%862.00K
----
-87.38%601.00K
-94.62%568.00K
-86.78%17.25M
2800.05%318.83M
132.75%4.76M
2195.00%10.56M
261138.00%130.52M
1647.85%10.99M
-98.24%2.05M
-76.73%460.00K
-106.10%-50.00K
174.26%629.00K
-43.62%116.14M
--1.98M
----

Revenue

By Business

Period:
No Data

By Region

Period:
No Data

FAQs

What is the total revenue of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its total revenue reached 85.21M, with a year-on-year change of 37.00K.

What are the current assets of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its current assets were 413.13M, with a year-on-year change of -5.01.

What are the total assets of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its total assets of 4D Molecular Therapeutics Inc were 566.71M, with a year-on-year change of 1.13.

What are the total liabilities of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its total liabilities of 4D Molecular Therapeutics Inc were 61.05M, with a year-on-year change of 22.64.

What is the total equity of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its total equity of 4D Molecular Therapeutics Inc was 505.66M, with a year-on-year change of -0.97.

What is the net operating income of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its net operating income of 4D Molecular Therapeutics Inc was -159.55M, with a year-on-year change of 15.06.

What is the net investment of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its net investment of 4D Molecular Therapeutics Inc was -92.97M, with a year-on-year change of 69.26.

What is the net financing of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its net financing of 4D Molecular Therapeutics Inc was 112.96M, with a year-on-year change of -66.51.

What is the Earnings Per Share (EPS) of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -2.42, with a year-on-year change of 18.90.

What is the net income of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its net income was -140.11M, with a year-on-year change of 12.90.

What is the net margin of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its net profit margin was -164.43, with a year-on-year change of 99.96.

What is the Return on Equity (ROE) of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its Return on Equity (ROE) was -27.57, with a year-on-year change of 29.86.

What is the Return on Assets (ROA) of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its Return on Assets (ROA) was -24.86, with a year-on-year change of 30.43.

What is the operating profit of 4D Molecular Therapeutics Inc?

According to 4D Molecular Therapeutics Inc's FY2025 earnings report, its operating profit was -159.55M, with a year-on-year change of 15.06.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy